A California-based biotech company is stealing the show on Wednesday after the company announced the data monitoring committee has recommended the continuation of its Phase 3 Sunrize study.

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

At a prespecified interim analysis conducted by an Independent Data Monitoring Committee, ivonescimab plus chemotherapy demonstrated a statistically significant and clinically meaningful ...

This decision was made after the committee reviewed early trial data and found that Truqap, in combination with docetaxel and androgen-deprivation therapy, was unlikely to meet main goals of ...

The Data Monitoring Committee (DMC) identified no safety concerns related to changes in ICH volumes, serious adverse events, neurological outcomes, or mortality. Bioxodes will release a second interim ...